Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

As Amanda Phommachanh, a 45-year-old realtor in Manassas, Virginia, describes it, she was on track with Wegovy to meet her ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Three-month interim data showed hyaluronic acid ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly cut its revenue guidance on Tuesday as it said demand for its weight loss and diabetes drugs would not meet ... anticipated in October. The new outlook would still mark a 32% jump ...

Weight loss drugs catapulted many into a new wellness era ... of new drugs looking to enter the market. Between August 2021 and August 2023, the prevalence of obesity among adults was 40.3 ...

The latest glucagon-like peptide 1 (GLP-1) receptor agonists have been heralded for their potential to not only boost weight loss and glucose ... tirzepatide, and new GLP-1 drugs in the research ...